Clinical Trial Update: Efficacy and Safety Study of Aplindore in Patients With Early Parkinson Disease [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Aplindore for efficacy and safety in early Parkinson disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Aplindore (aplindore)

Snippet

Sponsor: Neurogen Corporation | Conditions: Early Parkinson Disease | Phase 2 | Status: TERMINATED